Pharmaceutical Related Topics 
JD Supra: Mergers
JUNE 25, 2025
The case arose from Alexion Pharmaceuticals, Inc.’s A recent Delaware Chancery Court opinion offers a significant example of how courts may apply complex probability analysis to determine the amount of damages in an earnout dispute. s 2018 acquisition of Syntimmune, Inc.
CNBC: Investing
JUNE 6, 2025
Developing non-opioid pain drugs is a key focus for the industry, with Vertex Pharmaceuticals recently approving its Journavx Nav1.8 Other names on the list include Regeneron Pharmaceuticals and Bristol Myers Squibb. LLY YTD mountain Eli Lilly stock in 2025.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MergersCorp M&A International
NOVEMBER 16, 2024
firms, particularly in technology and pharmaceuticals, sectors that are considered critical to America’s future economic competitiveness. Although he often made headlines for his protectionist rhetoric, particularly in relation to China and trade deals, many countries continued to view the U.S. as a favorable destination for investment.
Cooley M&A
JANUARY 22, 2025
While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Immunology deals stood out, including Vertex Pharmaceuticals $4.9 from 2023. [1]
CNBC: Investing
JUNE 12, 2025
Last month, Goldman Sachs lifted its price target on the pharmaceutical giant to $176 from $172, placing Johnson & Johnson on its conviction list. Shares are up more than 7% in 2025, and the stock pays a dividend yield of about 3.4%. Analysts largely deem the stock a hold, seeing more than 9% upside from current levels, according to LSEG.
The New York Times: Banking
JULY 21, 2025
government employee were blocked from leaving, and a Japanese pharmaceutical executive was imprisoned, even as Beijing tries to court overseas investors. A Wells Fargo banker and a U.S.
Sidley Shareholder Litigation
JUNE 18, 2025
the sellers of a pharmaceutical business moved to dismiss the buyers’ claims for breaches of the representations and warranties in the parties’ purchase agreement, arguing they were time-barred by a five-year survival period in the agreement’s indemnification provision. In LGM Holdings, LLC v. Gideon Schurder, et al. ,
Expert insights. Personalized for you.
Let's personalize your content